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ABSTRACT
Background: DNA-PK and PARP inhibitors sensitize cancer cells to chemo- and 
radiotherapy. ETS transcription factors (EWS-FLI1) have been described as biomarkers 
for PARP-inhibitor sensitivity. Sensitivity to single agent PARP inhibitors has so far 
been limited to homologous recombination repair (HRR) deficient tumors, exploiting 
synthetic lethality.
Results: In clonogenic assays, single agent rucaparib LD50 values for continuously 
exposed cells were similar to those observed in HRR-defective cells (CAPAN-1 cell 
line, BRCA2 defective); however, both ES cell lines (TC-71, CADO-ES1) had functional 
HRR. In vivo rucaparib administration (10 mg/kg daily) showed no responses. In 
clonogenic assays, rucaparib enhanced temozolomide, camptothecin and radiation 
cytotoxicity, which was most profound for temozolomide (15–29 fold enhancement). 
NU7441 increased the cytotoxicity of etoposide, doxorubicin and radiation.
Materials and Methods: We assessed PARP1/2 (rucaparib) and DNA-PK (NU7441) 
inhibitors in Ewing sarcoma (ES) cell lines by performing growth inhibition and 
clonogenic assays. HRR was measured by RAD51 focus formation. Single agent 
rucaparib was assessed in an in vivo orthotopic model. 
Conclusions: Single agent rucaparib ES sensitivity in vitro was not replicated in 
vivo. DNA-PK and PARP inhibitors are good chemo-/radiosensitizers in ES. The future 
of these inhibitors lies in their combination with chemo-/radiotherapy, which needs 
to be evaluated in clinical trials.
INTRODUCTION
The Ewing sarcoma family of tumors (ESFT) 
is the second most common malignant bone or soft 
tissue tumor in childhood and adolescence, accounting 
for approximately 1.5% of all pediatric cancers. Most 
patients present with localized disease, but up to 25% have 
metastases at presentation [1]. Significant advances have 
been made over the past decades with 5-year event-free 
survival (EFS) rates for patients with localized disease 
increasing up to 70% [2, 3]. Despite intensive treatment 
regimes, survival rates for patients with primary metastatic 
disease have remained poor with 5-year EFS of 39% [2], 
which is reduced to 13% overall survival in patients 
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with relapsed disease [4]. Better treatment strategies for 
patients with ESFT are thus an urgent clinical need. 
One approach to increasing the efficacy of 
conventional chemo- or radiotherapy lies in its 
combination with chemo- or radio-sensitizing agents. 
Commonly used agents in Ewing sarcoma are the 
topoisomerase II poisons etoposide and doxorubicin, as 
well as ionizing radiation, which all cause DNA-double 
strand breaks (DSB). DSB are one of the most cytotoxic 
forms of DNA damage and if unrepaired may lead to cell 
death [5]. Homologous recombination repair (HRR) and 
non-homologous end joining (NHEJ) repair DSB lesions, 
with NHEJ being the most important repair pathway in the 
G0 and G1 phase of the cell cycle [6]. The DNA-dependent 
protein kinase (DNA-PK) is a central component of NHEJ 
[7, 8], and a highly potent and specific inhibitor of DNA-
PK (NU7441; 2-N-morpholino-8-dibenzothiophenyl-
chromen-4-one) has been used successfully in in vitro and 
in vivo models to sensitize colon cancer cells and CLL 
blasts to the effects of DNA-damaging chemo- and/or 
radiotherapy [9, 10].
Many second line treatment regimens also use 
topoisomerase I poisons (analogs of camptothecin: 
topotecan and irinotecan) and the DNA-methylating 
agent temozolomide that induce DNA single strand 
breaks. To repair the damage these agents inflict, intact 
DNA base excision repair (BER) and single strand break 
repair (SSBR) pathways are required. Poly(ADP-ribose) 
polymerase 1 (PARP1) is an essential element of SSBR. 
Inhibitors of PARP1 have been shown to increase the 
antitumor activity of temozolomide and topotecan in 
preclinical studies, including models of pediatric cancers 
[11, 12]. Several PARP inhibitors are in late-stage clinical 
trial, including combinations with temozolomide and 
topotecan (reviewed in [13, 14]) and the first study of the 
combination with temozolomide showed responses in 
10/32 patients [15]. However, the most promising clinical 
utility of PARP inhibitors at present is as single agents 
in HRR defective tumors, e.g. in BRCA 1 or BRCA 2 
defective tumors for which rucaparib recently obtained 
marketing authorization [16].
Ewing sarcoma (ES) cells are characterized by 
translocations involving the EWS gene from chromosome 
22 and a member of the ETS family of transcription 
factors, most commonly the FLI1 gene on chromosome 11. 
Both EWS and EWS-FLI1 proteins interact with BARD1, 
a putative tumor suppressor, which in turn associates with 
BRCA1 [17], potentially linking the Ewing sarcoma gene 
product with HRR. Both PARP1 and DNA-PK interact 
with EWS-FLI1 [18] and ESFT have high levels of PARP 
mRNA, protein and polymerase activity [19], and DNA-
PK catalytic subunit expression (kids cancer kinome 
database; http://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
In 2012, cells harboring the EWS-FLI1 translocation 
have been characterized as being particularly sensitive to 
PARP-inhibition by a high-throughput screening approach 
[20], and ES cells and xenografts were sensitive to the 
PARP-inhibitor olaparib [18]. We wanted to determine 
whether rucaparib as a single agent is synthetically 
lethal in ES cells as the EWS-ETS gene product may 
negatively influence HRR. Additionally we hypothesized 
that the abundance of PARP and DNA-PKcs implicate 
a heightened dependence on their activity that might 
render them particularly sensitive to chemo- and radio-
sensitization by PARP or DNA-PK inhibitors. 
We report here preclinical data showing that 
the cytotoxicity of single agent rucaparib was time 
dependent but in vivo experiments failed to demonstrate 
any measurable effect on tumor growth. The PARP-
inhibitor, rucaparib, sensitizes ES cells to temozolomide, 
camptothecin and ionizing radiation and the DNA-PK-
inhibitor NU7441 sensitizes ES cells to chemo- and 
radiotherapy. Our data strongly support the evaluation 
of these compounds in combination with chemo- and/or 
radio-therapy in in vivo models and clinical trials. 
RESULTS 
PARP1
PARP1 levels and inhibition of PARP1 activity by 
rucaparib
PARP1 expression and activity are known to vary 
widely between cell lines and individuals [21] and this 
could potentially impact on the response to cytotoxic 
drugs. We therefore measured PARP1 expression and 
activity in the ES cells. PARP1 protein was detected in 
both CADO-ES-1 and TC-71 cells (Figure 1A), with 
the level of PARP1 in CADO-ES-1 cells being lower 
than that in TC-71 cells, which in turn was lower than 
in the reference cell line, K562 (Figure 1A). Despite 
this difference, both cell lines showed similarly high 
PARP activity compared to the control cell line L1210 
(Figure 1B), and the PARP inhibitor rucaparib at 0.4 µM 
inhibited activity by > 95% in both cell lines (Figure 1B).
Single agent rucaparib activity
The impact of rucaparib as a single agent on the 
survival of TC-71 and CADO-ES1 cells was assessed 
using clonogenic survival assays. The standard assay 
consisted of a 24 h period of drug exposure, followed by 
harvesting and re-seeding for colony formation in drug-
free medium. In the standard assays, the ES cell lines TC-
71 and CADO-ES1 showed similar sensitivities to single 
agent rucaparib to that observed in growth inhibition 
assays, with LD50 values of 5.1 and 8.0 μM, respectively 
(Figure 2, left panel for TC-71 cell line). Since the 
PARP inhibitor cytotoxicity assays in ES reported in the 
literature [18, 20] involved continuous drug exposure 
for the duration of the experiment, clonogenic assays 
were also performed with re-drugging of rucaparib 
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every 3–5 days. In the experiments involving continuous 
drug exposure, both cell lines were significantly more 
sensitive to rucaparib than in our standard 24 h exposure 
assays, with LD50 values of 0.5 μM for TC-71 cells and 
LD50 of 1.0 μM for CADO-ES1 cells (Figure 2, right 
panel). HRR competent control cell lines (MCF-7, Hep3B) 
were less sensitive to rucaparib (LD50 of 3 and 10 μM, 
respectively). As expected, the HRR defective (BRCA 
mutant) cell line CAPAN-1 was sensitive towards PARP-
inhibition, with a LD50 of 1.8 μM. 
Rucaparib exposure for 24 h without harvesting/re-
seeding of TC-71 cells resulted in intermediate sensitivity 
to rucaparib compared to either the standard or continuous 
exposure clonogenic experiments (LD50 1.5 μM) (Figure 2, 
left panel).
Ewing cells are competent for homologous 
recombination repair (HRR) 
One possible explanation for the sensitivity of ES 
cells to rucaparib could lie in the interaction of EWS-
FLI1 gene products with BARD1 and its association with 
BRCA1 [17], which is essential for functional HRR. The 
HRR status of the ES cells was therefore explored.
HRR function was determined in TC-71 and 
CADO-ES1 cells with Hep3B cells as a positive control 
for functional HRR by measuring γH2AX and RAD51 
focus formation after 24 h exposure to 10 μM rucaparib. 
All 3 cell lines showed a significant increase in γH2AX 
focus formation, indicating the appearance of DSB after 
inhibition of PARP (Figure 3A). The increase in γH2AX 
focus formation was more than 10-fold in both ES cell 
lines, and about 8-fold in the control cell line Hep3B. 
Equally, all 3 cell lines showed a strong increase in 
RAD51 focus formation by at least 10-fold, thus there 
is no impairment of HRR in either cell line (Figure 3A, 
representative microscopy images Figure 3B).
Rucaparib as single agent shows no in vivo 
activity against TC-71 tumors
To determine if the cytotoxicity of rucaparib 
in cell culture experiments translated into an in vivo 
antitumor effect, immunocompromised mice implanted 
Figure 1: Confirmation of PARP and DNA-PK presence, activity and inhibition by rucaparib or NU7441. (A) Western 
Blot analysis of PARP1 in Cado-ES1, TC-71 and K562 cells. (B) PARP activity in CADO-ES1, TC-71 and L1210 cells, and its inhibition 
by 0.4 μM rucaparib. (C) Representative Western Blots for total and phosphorylated DNA-PKcs (pDNA-PK) in TC-71 and VH-64 cells (no 
ionizing radiation and without NU7441: lanes labelled “0 Gy”), and pDNA-PK signal in response to 10 Gy IR and increasing concentrations 
of NU7441. (D) Densitometric analysis of pDNA-PK levels: data from 3 separate experiments in TC-71 and VH-64 cells after ionizing 
radiation with 10 Gy, +/− NU7441, depicted are mean values +/− SEM.
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intrafemorally with TC-71 cells were treated with 
rucaparib. 
Mice treated with vehicle control (n = 5) or single 
agent rucaparib (n = 5, rucaparib 10 mg/kg daily on 5/7 
days for 6 weeks or until the end point for experiment 
was reached) demonstrated comparable tumor growth 
characteristics, without any evidence of tumor responses 
(Figure 4A, 4B). There was no significant clinical toxicity 
of single agent rucaparib at this dose. 
Weight changes of individual mice ranged between 
−9.5% to +2% total body weight for control animals, 
compared to −7.4% to −0.3% for rucaparib treated animals 
(data not shown). 
Growth inhibition assays using rucaparib
Rucaparib on its own did not cause any significant 
growth inhibition at 0.4 µM; the mean rucaparib GI50 
concentration for TC-71 cells was 5.0 µM and for CADO-
ES1 cells 4.7 µM, i.e. similar or slightly less sensitive 
than the confirmed HRR-competent MCF7 cell line (GI50 
2.4 µM) (Supplementary Figure 1).
TC-71 and CADO-ES1 cells were equisensitive 
to camptothecin (GI50: 3 and 2 nM), ionizing radiation 
(GI50: 2.2 and 1.8 Gy) and temozolomide (GI50: 0.3 and 
0.25 mM), respectively. Rucaparib at a concentration 
of 0.4 µM enhanced the cytotoxicity of temozolomide 
between 5- to 10-fold, of camptothecin 1.4- to 2-fold and 
ionizing radiation 1.4 fold (Supplementary Figure 2). 
Cytotoxicity assays using rucaparib
Chemo-/radio-potentiation
To determine if the reduced cell numbers observed 
in growth inhibition assays was due to cytotoxicity rather 
than mere cytostasis, we performed colony formation 
(clonogenic) assays.
Both TC-71 and CADO-ES1 cells were 
approximately equally sensitive to temozolomide with 
a LD50 of 0.28 mM (+/− 0.09 SEM) in TC-71 cells and 
0.33 mM (+/− 0.07 SEM) in CADO-ES1 cells. Rucaparib 
at a non-toxic concentration of 0.4 μM caused a very 
profound sensitization in both cell lines, with a 29 -fold 
(+/− 9 SEM) sensitization in TC-71 cells (mean LD50: 0.01 
mM) and a 15 -fold (+/− 3 SEM) sensitization in CADO-
ES1 cells (mean LD50: 0.02 mM), all results being highly 
statistically significant (2-way ANOVA: p < 0.0001) 
(Table 1; Figure 5B). 
Both cell lines displayed similar sensitivities to 
camptothecin, with a mean LD50 of 5.5 nM in TC-71 cells 
and 6.0 nM in CADO-ES1 cells. Rucaparib caused a 1.4-
fold potentiation (LD50 = 4.1 nM) in TC-71 cells and a 
2-fold potentiation (LD50 = 2.9 nM) in CADO-ES1 cells, 
but these effects were not, or marginally, statistically 
significant (p = 0.2 and 0.02).
The two cell lines were equally sensitive to ionizing 
radiation, with LD50 values of 1.1 Gy for both TC-
71 and CADO-ES1 cells. Rucaparib caused a modest 
radiosensitization of 1.7 -fold in TC-71 cells (mean 
LD50 0.7 Gy; p = 0.002) and of 1.4-fold in CADO-ES1 
cells (mean LD50 0.7 Gy, p = 0.08). All of the rucaparib 
combination data are summarized in Table 1.
DNA-PK
DNA-PKcs as a determinant of the effects of cytotoxic 
treatment 
To determine which classes of cytotoxic drugs 
are dependent on DNA-PK activity for repair of the 
damage they inflict, we performed experiments with 
Figure 2: The effect of drug exposure time in clonogenic assays. (A) Comparison of continuous exposure (12–14 days) to other 
clonogenic assays (24 h drug exposure with and without harvesting/reseeding) in TC-71 cells. (B) Clonogenic assays (continuous exposure) 
for rucaparib cytotoxicity in 5 different cell lines.
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DNA-PKcs deficient V3 cells, and their DNA-PKcs 
complemented derivative cell line V3-YAC, in which the 
gene for the human DNA-PKcs had been reintroduced 
via a yeast artificial chromosome (YAC). In clonogenic 
assays comparing the 2 cell lines, the LD50 values for 
topoisomerase II poisons (etoposide and doxorubicin), 
and LD50 values for ionizing radiation were significantly 
lower for the V3 (DNA-PKcs deficient) cells compared 
to the DNA-PKcs proficient V3-YAC cells, with dose 
reduction factors (DRF) between 2.4–2.9 (Supplementary 
Figure 3). In contrast, the alkylating agent 4-hydroperoxy-
cyclophosphamide, the topoisomerase I poison topotecan 
and the platinum drug cisplatin did not show any 
significant differences in their LD50 values (Supplementary 
Figure 3). Temozolomide was slightly more cytotoxic in 
DNA-PK deficient V3 cells, but the DRF was only 1.6. 
For these reasons, chemopotentiation by NU7441 of 
doxorubicin and etoposide only was investigated further.
Inhibition of DNA-PKcs by NU7441
Since DNA-PKcs expression and activity could 
potentially impact on drug- and radiosensitivity, these 
parameters were assessed by Western Blot. TC-71 and 
VH-64 had similar levels of DNA-PKcs protein (total 
DNA-PK) (Figure 1C). After DSB induction by ionizing 
radiation (10 Gy), there was a strong increase in signal 
intensity of phosphorylated DNA-PK at serine2056; a 
marker for DNA-PK activation. In both cell lines, co-
treatment of the cells with NU7441 revealed inhibition of 
DNA-PK activity in a concentration dependent manner, 
with a maximal inhibition at 1.0 µM NU7441 in both 
Table 1: Summary of clonogenic assay results
Cell line Treatment Clonogenic 
assays 
performed 
(n)
Mean LD50 
(+/–SEM)
Mean DRF50 
(+/–SEM)
2-way ANOVA
VH-64 Doxorubicin
Doxorubicin + NU7441
4 12.2 nM (1.3)
5.5 nM (0.26)
2.2 (0.2) P < 0.0001
Etoposide
Etoposide + NU7441
3 0.10 μM (0.01)
0.04 μM (0.01)
2.7 (0.4) P < 0.0001
IR
IR + NU7441
3 0.99 Gy (0.24)
0.36 Gy (0.02)
2.8 (0.7) P < 0.0001
TC-71 Doxorubicin
Doxorubicin + NU7441
3 13.4 nM (2.3)
6.3 nM (0.6)
2.1 (0.2) P = 0.0008
Etoposide
Etoposide + NU7441
3 0.28 μM (0.05)
0.04 μM (0.01)
6.7 (0.8) P < 0.0001
IR
IR + NU7441
3 1.32 Gy (0.07)
0.39 Gy (0.02)
3.4 (0.2) P < 0.0001
Temozolomide 
Temozolomide + rucaparib
3 0.28 (0.09)
0.01 (0.00)
29 (9) P < 0.0001
Camptothecin 
Camptothecin + rucaparib
3 5.5 nM (0.6)
4.1 nM (0.8)
1.4 (0.3) P = 0.2
Ionizing radiation
Ionizing radiation + rucaparib
4 1.08 Gy (0.24)
0.68 Gy (0.07)
1.7 (0.4) P = 0.002
CADO-ES1 Temozolomide 
Temozolomide +rucaparib
3 0.33 mM (0.07)
0.02 mM (0.003)
15 (3) P < 0.0001
Camptothecin 
Camptothecin + rucaparib
2 6.0 nM (1.3)
2.9 nM (0.3)
2.0 (0.2) P = 0.02
Ionizing radiation
Ionizing radiation + rucaparib
3 1.06 Gy (0.47)
0.74 Gy (0.31)
1.4 (0.1) P = 0.08
LD50: concentration of drug necessary to inhibit colony formation by 50%. SEM = Standard Error of Mean. DRF = 
dose reduction factor, calculated by dividing the LD50 results for the cells treated with cytotoxic alone and those of the 
corresponding cells treated with cytotoxic plus inhibitor.
Summary of all clonogenic assays in Ewing sarcoma cell lines evaluated for combinations of NU7441 (1.0 μM) or rucaparib 
(0.4 μM) with chemotherapeutic agents or ionizing radiation.
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cell lines (Figure 1D). All subsequent experiments were 
performed in the presence of 1.0 µM NU7441.
Chemo- and radio-potentiation using the DNA-
PK inhibitor NU7441
Using standard clonogenic assays on TC-71 and 
VH-64 cells, NU7441 alone was not toxic at 1.0 μM. 
In TC-71 cells, the NU7441 LD50 was 12 μM (n = 5 
clonogenic assays, Figure 5A, left panel), and in VH-64 
cells the LD50 was 16 μM (n = 1 clonogenic assay).
As predicted from the data presented in 
Supplementary Figure 3, NU7441 markedly potentiated 
the cytotoxicity of doxorubicin, etoposide and ionizing 
radiation when used at 1 μM (Figure 5A). NU7441 
enhanced the cytotoxicity of doxorubicin 2-fold at the 
LD50 concentration (doxorubicin alone: LD50 = 12–13 nM; 
doxorubicin with 1 μM NU7441 LD50 = 6 nM), and for 
both cell lines this effect was highly significant (2-way 
ANOVA p = 0.0008 for TC-71, p < 0.0001 for VH-64 
cells). Potentiation of etoposide cytotoxicity by NU7441 
was even greater (3–7 fold), with LD50 values for etoposide 
alone being 0.1 μM in VH-64 and 0.28 μM in TC-71 
cells, reduced to 0.04 μM by NU7441, the effect again 
being highly significant in both cell lines (2-way ANOVA 
p < 0.0001). In addition, NU7441 potentiated the effects 
of ionizing radiation in both cell lines, causing a 3-fold 
reduction in cell survival (ionizing radiation alone LD50 
= 1.0–1.3 Gy, ionizing radiation in presence of NU7441 
LD50 = 0.36–0.4 Gy; 2-way ANOVA p < 0.0001). All of 
the NU7441 combination data are summarized in Table 1.
DISCUSSION
Dysregulation of the DNA damage response has 
emerged over the past decade as both a contributor to 
Figure 3: The Ewing sarcoma cell lines TC-71 and CADO-ES1 are competent for homologous recombination repair. 
(A) Increase of γH2AX and rad51 foci after 24 h exposure to 10 μM rucaparib, relative to untreated control cells (100%), data for TC-71 
and CADO-ES1 cells with the mean +/– SD of 3 repeated experiments. (B) Representative microscopy images for data shown in 3A.
Oncotarget113424www.impactjournals.com/oncotarget
genomic instability and thus carcinogenesis, but also as 
a possible therapeutic opportunity, either for overcoming 
drug resistance or for exploiting synthetic lethality [6]. 
This study evaluated inhibitors of two different DNA 
repair pathways, i.e. base excision repair (BER)/single 
strand break repair (SSBR) and non homologous end 
joining (NHEJ), representing the pathways responsible 
for DNA single and double strand break repair. Ewing 
sarcoma was investigated as there is an urgent clinical 
need to improve treatment outcomes in inoperable, 
metastatic and relapsed patients. Pilot data in DNA-PKcs 
deficient and proficient cells demonstrated that sensitivity 
to both ionizing radiation and drugs commonly used in 
treatment strategies for Ewing sarcoma (doxorubicin, 
etoposide) was greater in the DNA-PKcs deficient cells 
(Supplementary Figure 1).
Inhibitors of DNA-PKcs have been used in vitro in 
colon cancer models and CLL blasts to enhance sensitivity 
to radio- and chemo-therapeutic treatments [9, 10], but 
pediatric malignancies so far have not been studied. The 
inhibitor NU7441 has improved potency and specificity 
over its predecessors NU7026 and LY294002, with an IC50 
of 14 nM and a > 100 fold specificity for DNA-PK over 
other PI3 kinase family members [22]. The expression 
and activity of DNA-PKcs was confirmed in ES cell lines, 
and concentration dependent inhibition by NU7441 was 
demonstrated. In in vitro assays, NU7441 was shown to 
sensitize ES cells to etoposide, doxorubicin and ionizing 
radiation with DRF50 values of 2.7–6.7, 2.1–2.2 and 2.8–3.4, 
respectively, all combinations being significantly different 
to the respective DNA-damaging agent alone in 2-sided 
ANOVA analyses. These are encouraging results that 
Figure 4: Results of single agent rucaparib in an orthotopic mouse model with TC-71 derived tumors. (A) TC-71 tumor 
growth as measured by radiance (p/s/cm2/sr). (B) Final bioluminescent imaging of each mouse on the respective day of culling.
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warrant further investigations in in vivo models. There are 
currently two DNA-PK inhibitors (MSC2490484A: DNA-
PK inhibitor, trials NCT02316197 and NCT02516813; 
CC-115: dual DNA-PK and TOR kinase inhibitor, trial 
NCT01353625) undergoing testing in Phase I clinical trials 
in adult patients, including those with Ewing sarcoma, 
as single agents and for MSC2490484A also as a radio-/
chemo-sensitizing agent.
PARP inhibition as an approach to the treatment of 
Ewing sarcoma has attracted increasing attention over the 
past years, after the publication by Garnett and colleagues 
identified the translocation EWS-FLI1 as a biomarker for 
PARP inhibitor sensitivity, and Brenner et al. reported 
that EWS-FLI1 interacts with PARP1 and influences its 
transcriptional activity. In other cancers, for example 
BRCA-deficient breast or ovarian cancer, sensitivity to 
PARP inhibition is due to defects in HRR, resulting in 
synthetic lethality. As EWS-FLI1 is reported to interact with 
BARD1, which associates with BRCA1, the HRR status of 
the ES cells was evaluated. Fluorescent microscopy assays 
for γH2AX and RAD51 foci clearly demonstrated that both 
ES cell lines were competent for HRR. 
Evaluation of the PARP1 inhibitor rucaparib in 
the two ES cell lines confirmed previous publications by 
Brenner and Garnett that ES cells are sensitive to single 
agent PARP1 inhibitors. However, in vitro sensitivity 
was strongly influenced by the type of assay used, i.e. 
there was a 10-fold difference in LD50 depending on the 
duration of exposure to rucaparib (24 h standard assay 
versus continuous exposure). In our in vivo experiments, 
mice were treated with single agent rucaparib at the dose 
of 10 mg/kg i.p. daily for 5 days/week for the duration 
of the experiment. This dose and schedule previously 
led to delayed tumor growth in various BRCA deficient 
in vivo models [23] but did not show any measurable 
effect on ES tumor growth. Despite the dose used in mice 
being well below the RP2D for rucaparib monotherapy 
in ovarian cancer (600 mg, resulting in a Cmax of 6 
µM/l, equivalent to 100mg/kg in mice [24, 25]), this 
result however confirms in vivo studies of other PARP 
inhibitors (BMN673, olaparib) performed by Norris and 
by Smith from the Pediatric Preclinical Testing Program, 
who also failed to show any significant responses or 
survival benefit by single agent PARP inhibitors [26, 27]. 
Figure 5: Representative graphs of clonogenic assays in TC-71 cells using NU7441 or rucaparib. (A) Representative 
clonogenic assays with NU7441 alone (24 h standard exposure) and 1.0 μM NU7441 in combination with doxorubicin, etoposide or 
ionizing radiation (IR). Points, mean of triplicate samples from three independent experiments; bars, SD. (B) Representative clonogenic 
assays with rucaparib alone (24 h standard exposure) and 0.4 μM rucaparib in combination with ionizing radiation, temozolomide and 
camptothecin. Points, mean of triplicate samples from three or four independent experiments; bars, SD.
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Furthermore, a Phase II clinical trial with olaparib in 
patients with recurred/progressive ESFT did not report 
any clinical responses [28]. It is therefore likely that other, 
as yet unknown, factors render Ewing sarcoma tumors 
insensitive to single agent PARP inhibition in vivo.
In combination with DNA-damaging agents, 
rucaparib was able to sensitize ES cells to the effects 
of temozolomide, camptothecin and ionizing radiation, 
with the chemo-potentiation of temozolomide being 
the most profound (mean DRF50 15–29). These results 
are in line with other published findings on chemo- and 
radio-potentiation both in vitro and in vivo ([29] and 
reviewed in [14]). Combinations of PARP inhibitors with 
chemotherapy (temozolomide or irinotecan, or both) in 
patients to date are still ongoing (e.g. NCT01858168, 
NCT02392793); however, systemic toxicity, especially 
myelosuppression, is anticipated.
Radio-potentiation via PARP- or alternatively DNA-
PK-inhibition potentially bears valuable clinical benefit, 
as it would lack systemic toxicity and could improve the 
outcome for inoperable, large or axial Ewing sarcomas. 
Lee et al. have recently published results on radio-
potentiation of ES cell lines by olaparib, both in vitro and 
using an in vivo preclinical model, with very encouraging 
results [30].
In summary, targeting DNA-repair pathways in 
combination with DNA-damaging agents is a promising 
approach to improving treatment strategies for Ewing 
sarcoma. Whereas inhibition of NHEJ by targeting DNA-
PKcs needs further preclinical investigation in vivo, 
PARP inhibitors as chemo-sensitizers for temozolomide 
and irinotecan are already being investigated in clinical 
trials for Ewing sarcoma and other cancers. Results of 
these trials are eagerly awaited, and ionizing radiation 
also needs to be investigated in combination with these 
PARP inhibitors, for the benefit of patients with metastatic, 
inoperable or relapsed Ewing sarcoma.
MATERIALS AND METHODS
Chemicals
Temozolomide was a gift from Cancer Research 
UK, London, United Kingdom. Doxorubicin, etoposide 
and camptothecin were purchased from Sigma Aldrich, 
UK. The DNA-PK inhibitor NU7441 was synthesized at 
the Northern Institute for Cancer Research as described 
previously [22] and dissolved at 2 mM in DMSO. The 
PARP-inhibitor rucaparib (formerly AG014699) was a 
gift from Clovis Oncology, Inc. (Boulder, CO, USA) and 
dissolved in 10 mM DMSO.
Cell lines and culture
The Chinese hamster ovary cell line V3 (deficient 
for DNA-PKcs) and its derivative cell line V3-YAC 
(transfected with the human gene for DNA-PKcs via a 
yeast artificial chromosome (YAC)) were a gift from Dr P. 
Jeggo (University of Sussex, UK).
The ES cell lines TC-71 [31] and VH-64 [32] with 
the typical translocation t(11;22)(q24;q12) resulting in the 
EWS/FLI-1 fusion transcript [33] were obtained as a gift 
from the department of pediatric hematology/oncology 
(Prof H. Jürgens University Hospital Münster, Germany). 
CADO-ES-1 cells [34] carrying the translocation t(21;22)
(q22;q12) and leading to an EWS/ERG fusion transcript 
[35] were purchased from DSMZ (Germany). V3, V3-YAC 
and all ES cell lines were cultured in RPMI 1640 medium 
(Sigma-Aldrich, UK) containing 10% (v/v) fetal bovine 
serum (FBS), penicillin (100 U/ml) and streptomycin (0.1 
mg/ml) at 37°C in a humidified atmosphere with 5% CO2 
in air. The medium for ES cells contained additional 2 mM 
L-glutamine. V3-YAC cells were cultured in the presence 
of the antibiotic G-418 sulfate (500 μg/ml, Invitrogen, 
California, USA) to retain the YAC.
The human BRCA2 defective pancreatic carcinoma 
cell line CAPAN-1 was obtained from ATCC (Manassas, 
VA, USA) and maintained in RPMI 1640 medium with 
15% (v/v) FBS [36]. The human breast cancer cell line 
MCF-7 and the hepatocellular carcinoma cell line Hep3B 
were obtained from the ATCC (Manassas, VA, USA), 
and both are HRR competent [23, 37]. MCF-7 cells were 
grown in the same medium as the ES cell lines, but without 
additional glutamine. Hep3B cells were cultured in 
DMEM/Ham’s F12 supplemented with 10% (v/v) FBS, 2 
mM L-glutamine, penicillin (100 U/ml) and streptomycin 
(0.1 mg/ml). All cell lines were regularly confirmed 
mycoplasma free (MycoAlertTM, Lonza) and used up to 
the 30th passage. Capan-1, Hep3B, MCF-7, VH-64 and 
TC-71 cells were authenticated by short tandem repeat 
profiling (LGC Standards) during the experimental work. 
All flasks and dishes intended for growing ES cells were 
collagen coated. For collagen coating, dishes were covered 
with a solution of rat tail collagen type I (BD Biosciences, 
0.2 mg/ml in 0.1 M glacial acetic acid) and allowed to dry 
overnight in a tissue culture hood.
Growth inhibition assays
Cell growth inhibition assays of exponentially 
growing TC-71, CADO-ES-1 and MCF-7 cells were 
performed in 6-well plates. Cells were seeded at a 
density of 1 × 104 cells per well to ensure exponential 
growth for the duration of the assay. Twenty-four hours 
post seeding, cells were exposed to medium containing 
varying concentrations of temozolomide or camptothecin, 
in the presence or absence of 0.4 µM rucaparib in a final 
concentration of 0.5% (v/v) DMSO. The concentration of 
0.4 µM was chosen as it had previously shown to enhance 
temozolomide and topotecan cytotoxicity in adult tumor 
cell lines [38]. In addition, cells were incubated with 
medium containing 0.4 µM rucaparib, and 0.5–1 h later 
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exposed to varying doses of ionizing radiation (Gulmay 
Medical RS320 Irradiation System, Gulmay Medical 
Limited, Surrey, UK). Controls were 0.5% DMSO 
or 0.4 µM rucaparib alone as appropriate. Cells were 
harvested by trypsinisation 72 h later and counted using a 
CoulterCounter (Beckman coulter UK Ltd.). Cell growth 
as a percentage of the DMSO or rucaparib alone controls 
was plotted using GraphPad Prism software (Version 6, 
GraphPad Software, La Jolla, USA). Concentrations of 
cytotoxic drugs alone or in combination with rucaparib 
that inhibited growth by 50% (GI50) were calculated using 
GraphPad Prism software.
Cell survival/cytotoxicity assays
Cell survival was determined by colony formation 
assays using one of 3 different procedures as follows: i) 
standard assay: exponentially growing cells were seeded 
onto 6-well plates or 6-cm petri dishes and 24 h later cells 
were exposed to drugs (temozolomide, camptothecin, 
doxorubicin, etoposide) with or without rucaparib (0.4 µM ) 
or NU7441 (1.0 µM) or the inhibitor alone for 24 h (0.4–
50 µM), or exposed to ionizing radiation (2.69 Gy/min at 
230 kV, 10 mA, Gulmay Medical Ltd., Surrey, UK), in the 
presence or absence of rucaparib (0.4 µM ) or NU7441 
(1.0 µM), and incubated for a further 24 h +/− rucaparib/
NU7441 as indicated. Cells were then harvested and re-
seeded for colony formation in 10 cm dishes as previously 
described [23]. Cells treated with medium containing 0.5% 
(v/v) DMSO or inhibitor only (rucaparib 0.4 µM, NU7441 
1.0 µM) were used as controls. ii) Cells were plated at 
low densities (50–1000) into 6-well dishes, and without 
harvesting or reseeding were either exposed continuously 
to different concentrations of rucaparib (0.04–50 µM) for 
the duration of the experiment (with the addition of fresh 
drug every 3–5 days); or iii) cells growing in 6-well dishes 
were exposed to rucaparib (0.4–50 µM) for 24 h followed 
by drug-free medium for the rest of the experiment. The 
usual assay performed was the standard assay as in i), 
only for rucaparib single agent assays were additional 
experiments (i.e. ii and iii) performed.
After 12–14 days at 37°C, colonies were stained 
with 0.4% (w/v) crystal violet and counted using an 
automated colony counter (ColCount, Oxford Optronics 
Ltd., Oxford, UK). As the VH-64 cells did not form 
satisfactory colonies on standard collagen-coated dishes, 
they were seeded into 6-cm Petri dishes containing a 
0.16% (w/v) agarose-medium mixture (SeaKem ME 
Agarose, Lonza, Cologne, Germany) and stained after 
incubation for 12 days using 0.5 mg/ml MTT (Sigma, 
UK) for 2–5 h at 37°C. The cloning efficiency (%) was 
calculated as [(number of colonies counted/number of cells 
seeded) × 100] and cell survival/colony formation (%) 
was calculated as [(drug-treated cell cloning efficiency/
control cell cloning efficiency) × 100]. The concentration 
of drug necessary to inhibit colony formation by 50% 
(LD50) was calculated, and the ratios of LD50 results for the 
cells treated with cytotoxic alone and the corresponding 
cells treated with cytotoxic plus inhibitor gave the 
dimensionless dose reduction factor50 (DRF50). Cells were 
plated in triplicates for each drug concentration and each 
chemo- or radio-potentiation experiment was repeated at 
least 2 times.
Western blotting
Western blots for PARP1 were performed using 
the anti-PARP1 C2–10 primary antibody (Trevigen, MD, 
USA), as described previously [21].
To measure DNA-PK activity and its inhibition 
as well as total cellular DNA-PKcs protein levels, cells 
were either left un-irradiated or exposed to 10 Gy in the 
presence or absence of NU7441 (0.1–5.0 µM) and protein 
extraction was performed as previously described [39]. 
Briefly, after incubating for 30 minutes cellular proteins 
were extracted in Phosphosafe extraction reagent (Merck, 
UK), subjected to electrophoresis on 3–8% (w/w) Tris-
Acetate XT-Criterion Gels (Biorad, UK), transferred 
onto nitrocellulose membranes (Hybond C, Amersham 
Biosciences, UK) and probed with mouse monoclonal 
DNA-PKcs (ab1832, Abcam, Cambridge, UK), rabbit 
polyclonal anti-pSer2056 DNA-PKcs (ab18192, 
Abcam, Cambridge, UK) and anti-Actin (Ab-1) mouse 
monoclonal antibody (JLA20) (Calbiochem, Nottingham, 
UK). Following exposure to HRP conjugated secondary 
antibodies and ECL development, expression was 
measured by chemiluminescence detection (Fuji LAS; 
Raytek, Sheffield UK).
PARP activity assay
PARP activity and its inhibition was measured 
by a GCLP-validated immunoblot assay that has been 
previously described, both for clinical material and cell 
cultures [12, 40]. This assay measures poly ADP-ribose 
(PAR) formation in permeabilised cells following maximal 
stimulation by blunt ended oligonucleotides, mimicking 
DNA breaks, in the presence of excess NAD+. PAR 
formation was measured using anti-PAR 10H antibody 
(kind gift from Prof Dr A Burkle, University of Konstanz, 
Germany) followed by chemiluminescence detection as 
described above. 
Double strand break (DSB) induction and repair 
DSB were counted by measuring phosphorylation 
of histone H2AX (γH2AX) by DNA-PK and ATM, 
leading to the formation of a γH2AX focus at the site of 
the lesion [41]. Rucaparib leads to the formation of DSB 
by inhibiting SSBR [23]. Measurement of nuclear RAD51 
focus formation was used as a marker for functional 
HRR [42]. 
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For the combined assay, TC-71, CADO-ES1 or 
Hep3B cells as an HRR competent positive control cell 
line were grown on round 22 mm collagen coated (for 
TC-71 and CADO-ES1) glass coverslips (BD Biosciences, 
UK) in standard 6-well plates for at least 24 h. Cells were 
then exposed to 10 μM rucaparib or vehicle control (i.e. 
DMSO) for 24 h at 37°C, washed twice with cold PBS, 
fixed with ice-cold 4% paraformaldehyde and probed 
for γH2AX and RAD51 using immunofluorescence 
microscopy with image analysis using ImageJ as 
previously described [23, 43]. Foci in 60-289 cells were 
counted for each cell line and treatment, on average 166 
cells per experiment. 
Determination of in vivo anticancer activity
All animal experiments were performed according to 
current UK Home Office regulations, complying with the 
3R principles (Home Office licence number PPL60/3846). 
Immunocompromised male rag2–/–γc–/– mice were used and 
implanted intrafemorally with 5 × 105 transduced TC-71 
cells as previously described [44]. The TC-71 cells had 
been transduced with a lentiviral vector encoding both 
enhanced green fluorescent protein (EGFP) and firefly 
luciferase (fLuc) allowing to image growing tumors with 
bioluminescent imaging. Animals were randomly assigned 
to treatment with vehicle control (dH2O, 10 ml/kg i.p.) 
or with rucaparib 10 mg/kg i.p. on days 1–5 on a 7-day 
cycle for a duration of 6 cycles. The dose of 10 mg/kg 
i.p. daily x5 for 6 cycles was selected as it had been well 
tolerated previously and had shown significant delays in 
tumor growth in a BRCA1 and BRCA2 mutated mouse 
models [23]. Treatment of mice started on day 9 after 
intrafemoral injection of tumor cells, followed by weekly 
bioluminescent imaging as previously described [44]. 
Statistical analyses
All graphs were plotted with the help of Graph Pad 
Prism software and statistical tests (2-way ANOVA) were 
calculated using GraphPad Prism (version 6.0).
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